Dr Reddy
-
{
- All
- News
- Videos
-
Dr Reddy's Esophageal Cancer Drug Zytorvi Gets India's Drug Controller Approval
The drug has been approved in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC, the pharma company said in a release.
-
India To Get First Dengue Vaccine In 2027: What Is QDENGA?
The arrival of QDENGA could add another layer to India's dengue prevention strategy. However, vaccination is expected to complement rather than replace existing public-health measures.
-
Why Did Dr Reddy's Shares Rise Nearly 2% In Trade Today? Key Details Inside
At 9:23 am, Dr Reddy's shares were trading 1.82% higher at Rs 1,192.40 per share, compared with a 0.27% rise in the BSE Sensex, which was at 74,516 levels.
-
Dr Reddy's Shares Fall Nearly 7% After Weaker-Than-Expected Q1 Results
Dr Reddy's shares fell upto 6.92%, later recovering slightly to dip by 2.82% at Rs 1,149.50 apiece.
-
'Won't Do Anything Special': Dr Reddy's Stands Pat On Trump's Tariff Threat; Warns Of US Price Hikes
Dr Reddy's CEO said proposed US tariffs on generic medicines will raise drug prices for American consumers, while ruling out any immediate shift in manufacturing.
-
Dr Reddy's Semaglutide Delay Sparks Brokerage Divide; Kotak Calls It 'Another Dose Of Disappointment' — Check Target
Brokerages have retained their ratings but highlighted concerns over the delay in semaglutide commercialisation following an API impurity issue disclosed by the company during its earnings call.
-
Dr Reddy's Wins Higher Target As HSBC Backs Its Global Expansion Strategy — Details Inside
HSBC has raised its FY27-28 earnings per share estimates by 2.8% to 4.6%, reflecting a more optimistic outlook for semaglutide and abatacept.
-
Dr Reddy's To Launch Generic Ozempic In India From March
The company is awaiting further guidance from Health Canada after it filed a response in November to a notice of non-compliance.
-
Dr Reddy's Laboratories Shares Rise Despite Q3 Profit Decline — Here's Why
The company continues to focus on disciplined execution of its strategic priorities of base business growth, pipeline advancement, operational efficiencies, and select inorganic opportunities, to create long-term value for our stakeholders, the drug maker said in a statement.
-
Cyber Fraud Targeting Drugmaker Dr Reddy's Busted, Rs 2.16 Crore Recovered
Group Pharmaceuticals was due to receive a payment of Rs 2.16 crore from Dr. Reddy's Laboratories. However, hackers gained access to their emails and diverted funds.
-
Dr Reddy's Laboratories Declares Dividend Of Rs 8 Per Share
The record date to determine the eligible shareholders for the dividend is set as July 10.
-
Dr. Reddy’s Share Price Rises 3% As Firm Dismisses Report On Job Cuts
The pharma major called a Business Standard report on senior-level exits and cost trimming ‘factually incorrect’.
-
Dr. Reddy's Q2 Results Review: Brokerages Maintain Cautious Stance As US Challenges Loom
Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.
-
Nestle India And Dr Reddy's Laboratories Form Joint Venture Company
The partnership was made to combine the established reputed range of nutritional products of Nestlé Health Science with the nutraceuticals portfolios of Dr. Reddy’s Labs.
-
Dr Reddy's Inks Agreement With Takeda For Patented Peptic Disorder Drug Sale
Vonoprazan is an active potassium competitive acid blocker, used to treat reflux esophagitis.
-
Dr Reddy's Esophageal Cancer Drug Zytorvi Gets India's Drug Controller Approval
The drug has been approved in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC, the pharma company said in a release.
-
India To Get First Dengue Vaccine In 2027: What Is QDENGA?
The arrival of QDENGA could add another layer to India's dengue prevention strategy. However, vaccination is expected to complement rather than replace existing public-health measures.
-
Why Did Dr Reddy's Shares Rise Nearly 2% In Trade Today? Key Details Inside
At 9:23 am, Dr Reddy's shares were trading 1.82% higher at Rs 1,192.40 per share, compared with a 0.27% rise in the BSE Sensex, which was at 74,516 levels.
-
Dr Reddy's Shares Fall Nearly 7% After Weaker-Than-Expected Q1 Results
Dr Reddy's shares fell upto 6.92%, later recovering slightly to dip by 2.82% at Rs 1,149.50 apiece.
-
'Won't Do Anything Special': Dr Reddy's Stands Pat On Trump's Tariff Threat; Warns Of US Price Hikes
Dr Reddy's CEO said proposed US tariffs on generic medicines will raise drug prices for American consumers, while ruling out any immediate shift in manufacturing.
-
Dr Reddy's Semaglutide Delay Sparks Brokerage Divide; Kotak Calls It 'Another Dose Of Disappointment' — Check Target
Brokerages have retained their ratings but highlighted concerns over the delay in semaglutide commercialisation following an API impurity issue disclosed by the company during its earnings call.
-
Dr Reddy's Wins Higher Target As HSBC Backs Its Global Expansion Strategy — Details Inside
HSBC has raised its FY27-28 earnings per share estimates by 2.8% to 4.6%, reflecting a more optimistic outlook for semaglutide and abatacept.
-
Dr Reddy's To Launch Generic Ozempic In India From March
The company is awaiting further guidance from Health Canada after it filed a response in November to a notice of non-compliance.
-
Dr Reddy's Laboratories Shares Rise Despite Q3 Profit Decline — Here's Why
The company continues to focus on disciplined execution of its strategic priorities of base business growth, pipeline advancement, operational efficiencies, and select inorganic opportunities, to create long-term value for our stakeholders, the drug maker said in a statement.
-
Cyber Fraud Targeting Drugmaker Dr Reddy's Busted, Rs 2.16 Crore Recovered
Group Pharmaceuticals was due to receive a payment of Rs 2.16 crore from Dr. Reddy's Laboratories. However, hackers gained access to their emails and diverted funds.
-
Dr Reddy's Laboratories Declares Dividend Of Rs 8 Per Share
The record date to determine the eligible shareholders for the dividend is set as July 10.
-
Dr. Reddy’s Share Price Rises 3% As Firm Dismisses Report On Job Cuts
The pharma major called a Business Standard report on senior-level exits and cost trimming ‘factually incorrect’.
-
Dr. Reddy's Q2 Results Review: Brokerages Maintain Cautious Stance As US Challenges Loom
Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.
-
Nestle India And Dr Reddy's Laboratories Form Joint Venture Company
The partnership was made to combine the established reputed range of nutritional products of Nestlé Health Science with the nutraceuticals portfolios of Dr. Reddy’s Labs.
-
Dr Reddy's Inks Agreement With Takeda For Patented Peptic Disorder Drug Sale
Vonoprazan is an active potassium competitive acid blocker, used to treat reflux esophagitis.
